

Elevated Plasma Complement Factors in *CRB1*-associated Inherited Retinal Dystrophies

Lude Moekotte,¹ Joke H. de Boer,¹ Sanne Hiddingh,¹ Aafke de Ligt,¹ Xuan-Thanh-An Nguyen,² Carel B. Hoyng,³ Chris F. Inglehearn,⁴ Martin McKibbin,^{4,5} Tina M. Lamey,⁶ Jennifer A. Thompson,⁷ Fred K. Chen,^{6,7} Terri L. McLaren,^{6,7} Alaa AlTalbishi,⁸ Daan M. Panneman,⁹ Erica G.M. Boonen,⁹ Sandro Banfi,^{10,11} Béatrice Bocquet,^{12,13} Isabelle Meunier,^{12,13} Elfride De Baere,^{14,15} Robert Koenekoop,^{16,17} Monika Ołdak,¹⁸ Carlo Rivolta,^{19,20,21} Lisa Roberts,²² Raj Ramesar,²² Rasa Strupaitė-Šileikienė,²³ Susanne Kohl,²⁴ G. Jane Farrar,²⁵ Marion van Vugt,²⁶ Jessica van Setten,²⁶ Susanne Roosing,⁹ L. Ingeborgh van den Born,²⁷ Camiel J.F. Boon,^{2,28} and Maria M. van Genderen,^{1,29} and Jonas J.W. Kuiper¹

¹ Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands

² Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands

³ Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands

⁴ Division of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom

⁵ Department of Ophthalmology, St. James's University Hospital, Leeds, United Kingdom

⁶ Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Western Australia, Australia

⁷ Australian Inherited Retinal Disease Registry & DNA Bank, Department of Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

⁸ St John of Jerusalem Eye Hospital Group, East Jerusalem, Palestine

⁹ Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands

¹⁰ Telethon Institute of Genetics and Medicine, Pozzuoli, Italy

¹¹ Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy

¹² Institute for Neurosciences of Montpellier (INM), University of Montpellier, INSERM, Montpellier, France

¹³ National Reference Center for Inherited Sensory Diseases, University of Montpellier, CHU, Montpellier, France

¹⁴ Department of Biomolecular Medicine, Ghent University, Ghent, Belgium

¹⁵ Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium

¹⁶ McGill University Health Center (MUHC) Research Institute, Montreal, QC, Canada

¹⁷ Departments of Paediatric Surgery, Human Genetics, and Adult Ophthalmology, McGill University Health Center, Montreal, QC, Canada

¹⁸ Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland

¹⁹ Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland

²⁰ Department of Ophthalmology, University of Basel, Basel, Switzerland

²¹ Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom

²² UCT/MRC Precision and Genomic Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

²³ Center of Eye Diseases, Clinic of Ear, Nose, Throat, and Eye Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

²⁴ Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany

²⁵ The School of Genetics & Microbiology, The University of Dublin Trinity College, Dublin, Ireland

²⁶ Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands

²⁷ Department of Ophthalmology, Het Oogziekenhuis Rotterdam, Rotterdam, the Netherlands

²⁸ Department of Ophthalmology, Amsterdam UMC, Amsterdam, the Netherlands

²⁹ Bartiméus, Diagnostic Centre for complex visual disorders, Zeist, the Netherlands

Word count:

Word count main text (excl. title page, legends, and references):

Funding: Bartimeus Foundation (**LM, JHdB, SH, AdL, XN, LlvdB, CB, MMvG, JJWK**), VHRN vision health research network and FBC fighting blindness Canada (**RK**), Swiss National Science Foundation (grant 204285) and European Union (grant EJP-RD19-234, Solve-Ret) (**CR**)

Abstract

Objective: To determine the profile of inflammation-related proteins and complement system factors in serum of *CRB1*-associated inherited retinal dystrophies (*CRB1*-IRDs).

Design: A case-control study.

Subjects, Participants, and/or Controls: A cohort of 30 Dutch *CRB1*-IRD patients and 29 Dutch healthy controls (HC) (Cohort I), and a second cohort of 123 *CRB1*-IRD patients from 14 countries and 1292 controls (Cohort II) were used in this study.

Methods: Quantitative 370-plex targeted proteomics in blood plasma and genotyping of the single nucleotide variant (SNV) rs7535263 in the *CFH* gene.

Main Outcome Measures: Plasma concentrations of inflammation-related proteins and the genotype of the SNV rs7535263.

Results: *CRB1*-IRD patients showed increased plasma levels of complement system and coagulation cascade proteins compared to healthy controls. Complement Factor I [CFI], Serpin Family D1 [SERPIND1], and Complement Factor H [CFH] were significantly elevated ($q < 0.05$, adjusted for age and sex), which correlated (Pearson's correlation coefficient > 0.6) with higher levels of plasma Complement Component 3 [C3] ($q = 0.064$). The most enriched pathway in patients was the "Complement cascade" (R-HSA-166658, $P_{adj} = P = 3.03 \times 10^{-15}$). An analysis of the genotype of *CFH* variant rs7535263, which is in close physical proximity to the *CRB1* gene and is associated with other retinal conditions by influencing plasma complement levels, revealed significantly skewed allele distribution specifically in Dutch patients (A allele of rs7535263, odds ratio (OR) [95%CI = 2.85 [1.35-6.02], $P = 6.19 \times 10^{-3}$), but not in a global case-control cohort ($P = 0.12$). However, *CRB1* missense variants that are common in patients display strong linkage disequilibrium (LD) with rs7535263 in *CFH* in the UK Biobank ($D' = 0.97$ for p.(Cys948Tyr); $D' = 1.0$ for p.(Arg764Cys)), indicating that genetic linkage may influence plasma complement factor levels in *CRB1*-IRD patients.

Complement factors in *CRB1*-IRDs

After accounting for the *CFH* genotype in the proteomic analyses, we also detected significantly elevated plasma levels of Complement Factor H Related 2 [CFHR2] in *CRB1*-IRD patients ($q = 0.04$).

Conclusions: *CRB1*-IRDs are characterized by changes in plasma levels of complement factors and proteins of the innate immune system, which is influenced by common functional variants in the *CFH-CFHR* locus. This indicates that innate immunity is implicated in *CRB1*-IRDs.

Keywords: inherited retinal dystrophy, *CRB1*, proteomics, complement, *CFH*, inflammation

1 Introduction

2 The *Crumbs homolog 1 (CRB1)* gene (also known as *RP12*) is a transmembrane protein that
3 functions in the integrity preservation of the photoreceptor layer of the retina. *CRB1*
4 pathogenic variants cause a spectrum of rare autosomal recessive inherited retinal
5 dystrophies (*CRB1*-IRDs) characterized by photoreceptor cell death and early visual
6 impairment.¹⁻³ There are many pathogenic variants associated with *CRB1*-IRDs, and the
7 clinical phenotypes vary considerably in severity of disease.^{1,3} Although some correlation
8 between *CRB1* genotype and clinical phenotypes can be found,⁴ overall there is surprisingly
9 little genotype-phenotype correlation, even among cases with identical pathogenic
10 variants.^{1,3} Therefore, it has been hypothesized that phenotypic variation among patients
11 may be caused by factors other than the underlying *CRB1* pathogenic variants.¹

12 The presence of vitreous inflammation or cystoid macular edema (CME) in some patients
13 with *CRB1*-IRDs suggests that inflammatory pathways may be involved in the
14 pathophysiology.^{5,6} Indeed, inflammatory genes and complement factors are upregulated in
15 the retinas of rd8 mice homozygous for a *Crb1* gene pathogenic variant.^{1,5-9} Furthermore, we
16 previously showed that patients with *CRB1*-IRDs exhibit changes in their peripheral blood T
17 cells and dendritic cells.^{6,10} These findings suggest that variability of immune responses
18 between patients may contribute to differential clinical phenotypes, but there have been few
19 studies that examine the immune profiles of *CRB1*-IRD patients.^{6,10}

20 A way to study immune profiles is by examining blood proteins, which contribute to immune
21 responses and function by modifying the signaling of cytokines, triggering acute-phase
22 reactions, and activating complement cascades. Targeted proteomics allows the accurate
23 quantification of hundreds of blood proteins in patient samples to determine, in-depth, the
24 immune profile of disease and identify disease-related mechanisms.¹¹ This technique has
25 provided insight in the blood proteome of diverse eye conditions such as age-related

Complement factors in *CRB1*-IRDs

26 macular degeneration (AMD), retinopathy of prematurity, uveitis, uveal melanoma, and
27 diabetic retinopathy.^{12–18}

28 In this study, we conducted targeted 370-plex proteomics of blood plasma proteins in *CRB1*-
29 IRD patients and healthy controls to determine the plasma concentrations of inflammation-
30 related proteins. In the same cohort, and in a validation cohort, we determined the *CFH* gene
31 variant rs7535263 to test for associations between protein expression and genotype.

32 **Methods**

33 **Patients**

34 This study was performed in compliance with the guidelines of the Declaration of Helsinki
35 and has the approval of the local Institutional Review Board (University Medical Center
36 Utrecht (UMCU)). In total, 30 patients were referred to the UMCU from the Amsterdam
37 University Medical Centers, Leiden University Medical Center, Bartiméus Diagnostic Center
38 for complex visual disorders, The Rotterdam Eye Hospital and Rotterdam Ophthalmic
39 Institute, and Groningen University Medical Center for recruitment at the outpatient clinic of
40 the department of Ophthalmology of the UMCU (MEC-14-065). Each patient provided written
41 informed consent before participation and blood collection. The *CRB1*-IRD diagnosis was
42 established by ophthalmic examination, imaging, full field electroretinography, and next-
43 generation sequencing or whole-exome sequencing. Patients were considered to have a
44 molecularly confirmed *CRB1*-IRD in cases where they harbored two or more rare functional
45 variants (i.e., disease-causing *CRB1* variants, such as missense, deletions, loss-of-function,
46 or splice altering variants) affecting both gene copies of *CRB1* (**Supplementary Table 1**).

Complement factors in *CRB1*-IRDs

47 We excluded patients with systemic inflammatory conditions at the time of sampling and/or
48 patients that received systemic immunomodulatory treatment. At the day of inclusion,
49 patients were examined by visual acuity measurement, and slit lamp examination was
50 performed by an experienced uveitis specialist for assessment of vitreous cells and vitreous
51 haze.

52 Next, we obtained blood from 29 anonymous age-matched healthy blood bank donors (HC)
53 with no history of ocular inflammatory disease who gave broad written informed consent at
54 the research blood bank of the University Medical Center Utrecht (The “Mini Donor Dienst”).

55 **Targeted blood proteomics**

56 Venous blood samples were collected in EDTA Lavender Top Tubes (#362084, BD
57 Biosciences, Franklin Lakes, USA) and then centrifuged for 10 min (400g) within an hour of
58 blood collection (**Supplementary Table 2**). Plasma was transferred to a Falcon™ 15 mL
59 Conical Centrifuge Tube and centrifuged for 10 min (1500g), after which the cleared plasma
60 was transferred and stored in Micronic 1.4 mL round bottom tubes (#MP32022, Micronic,
61 Lelystad, the Netherlands) at -80 degrees Celsius. For proteomic analysis of plasma, patient
62 and control samples were randomized over three 96 well plates (#72.1980, Sarstedt,
63 Nümbrecht, Germany) and sealed (#232698, Thermo Fisher, Waltham, USA) prior to
64 shipment to the Olink Proteomic facility at the Erasmus Medical Center, Rotterdam, the
65 Netherlands. We used the *Olink Explore 384 Inflammation II* panel for targeted proteomics of
66 blood plasma. This Olink technology is based on Proximity Extension Assays (PEA) coupled
67 with NGS and is capable of the simultaneous relative quantification of 370 protein analytes.⁷

68 **TaqMan® SNP genotyping**

69 Genomic DNA of 59 peripheral mononuclear blood samples in RLT Plus lysis buffer
70 (#1053393, Qiagen, Hilden, Germany) was isolated with the AllPrep DNA/RNA/miRNA
71 Universal Kit (#80224, Qiagen, Hilden, Germany). Next, we determined the rs7535263

Complement factors in *CRB1*-IRDs

72 variant with the TaqMan® SNP genotyping technology (#4351379, Thermo Fisher, Waltham,
73 USA). Genotypes were called using QuantStudio 12K Flex software (Thermo Fisher,
74 Waltham, USA). Linkage disequilibrium (r^2 or D') data for rs7535263 in the CEU population
75 of the 1000 genomes were obtained with the *LDproxy tool* with genome build *GRCh37* in
76 *LDlink*.¹⁹ The estimated recombination rate for CEU (build *GRCh37*) generated by Adam
77 Auton was obtained via the 1000 Genomes ftp site
78 ([ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_r](ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_rates/)
79 [ates/](ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_rates/)).²⁰ We calculated the LD between rs7535263 in *CFH* and *CRB1* missense variants
80 p.(Cys948Tyr) and p.(Arg764Cys) in phased whole-genome sequencing data of ~150,000
81 individuals of the UK Biobank using the *--ld* function in plink 2.0.^{21,22} The UK Biobank has
82 ethical approval from North West–Haydock Research Ethics Committee (REC reference:
83 16/NW/0274). Details of the UK Biobank study have been described in detail previously.²³
84 This research has been conducted using the UK Biobank Resource under Application
85 Number 24711.

86 TaqMan® genotyping of rs7535263 was also performed in an independent validation cohort
87 (Cohort II) of 123 *CRB1*-IRD patients from United Kingdom, Australia, Palestine, Italy,
88 France, Belgium, the Netherlands, Canada, Poland, Switzerland, South Africa, Lithuania,
89 Germany, and Ireland (MEC-2010-359) and 1292 Dutch controls from the amyotrophic
90 lateral sclerosis study.²⁴ All patients provided written informed consent for genetic testing at
91 the centre of recruitment. *CRB1*-associated genetic diagnoses were made by targeted gene
92 Sanger sequencing or established recently through RP/LCA smMIPs sequencing.²⁵
93 TaqMan® SNP genotyping (#4351379, Thermo Fisher, Waltham, USA) was performed on
94 genomic DNA following the same procedure as described above by the laboratory of the
95 Department of Human Genetics, Radboud University Medical Center, Nijmegen, the
96 Netherlands.

97 **Statistical analyses**

Complement factors in *CRB1*-IRDs

98 Proteome analyses were performed on *Normalized Protein eXpression* (NPX) units from the
99 output of the Olink analysis in R and R studio (version 4.2.2) using the Olink® Analyze R
100 package.^{26,27} One protein, TNFSF9, had 13 missing data points and 10 proteins did not pass
101 quality control (Olink assay report). These proteins were removed prior to group analyses.
102 The *prcomp* function of R base was used to perform principal component analysis (PCA).
103 Differential expression analysis was performed using a likelihood ratio test (LRT) with age
104 and sex as covariates in the models and we used the *qvalue* package from Bioconductor to
105 correct *P* values for multiple testing.²⁸ Over-representation analysis (or enrichment) was
106 performed on proteins with nominal significant differential expression levels ($P < 0.05$) with
107 the *ClusterProfiler* R package and using the WikiPathways database as a reference.²⁹ The
108 results were plotted using the *dotplot* function of the *enrichplot* R package and the *P*-values
109 from enrichment analysis were adjusted with the Benjamini-Hochberg (BH) procedure, using
110 the *p.adjust* function in R base, and *P*-values (*Padj*) < 0.05 were considered statistically
111 significant.³⁰ Disease association for rs7535263 was assessed with *Plink* using the Fisher's
112 exact test and expressed as the odds ratio with a 95% confidence interval. We performed a
113 likelihood ratio test (LRT) to assess the relation between the genotype and the protein
114 expression levels and visualized the results using the *corrplot* R package.³¹ Other figures
115 were generated with the *ggplot2* package.³² The explained variance (R^2) by the genotype of
116 rs7535263 of plasma proteins was calculated using the squared Pearson correlation
117 coefficient (r^2) using the *cor* function in R base.


118 **Results**

119 **Generation of a high-quality plasma proteome of *CRB1*-IRD patients**

120 To explore the composition of inflammatory mediators in the plasma proteome of *CRB1*-IRD
121 patients, we conducted 370-plex targeted proteomics using proximity extension assays
122 combined with *next-generation sequencing* in a cohort of 30 patients and 29 healthy
123 controls. To ensure high-quality data for quantitative proteomic analysis, we first applied a

Complement factors in *CRB1*-IRDs

124 stringent quality control process. We first filtered out low-quality analytes by removing
125 proximity extension assays that did not pass quality control in all plasma samples, resulting
126 in 358 (97%) proteins that passed this filtering step. We detected no outlier plasma samples
127 as shown by the relatively comparable sample median and sample interquartile range (IQR)
128 as well as *Normalized Protein eXpression* (NPX, the protein expression unit which is in Log₂
129 scale) distribution between plasma samples (**Figure 1A and 1B**). However, nine plasma
130 samples exhibited internal controls deviating >0.3 NPX from the plate median which were
131 also removed from the dataset (**Figure 1B**). Principal component analysis on the 50
132 remaining plasma samples revealed a moderate plate effect that we mitigated by using the
133 *Combat* algorithm to account for batch effects (**Figure 1C and 1D**). As a result, a high-
134 quality proteomic dataset was generated for downstream analysis.



135

Complement factors in *CRB1*-IRDs

136 **Figure 1. Quality control of plasma proteomic profiling by proximity extension assays combined with**
137 **next generation sequencing. A)** The median and the interquartile range (IQR) of the distribution of *Normalized*
138 *Protein eXpression* (NPX) values for each of 59 plasma samples (in blue) measured in this study and internal
139 plate and array controls (in grey). The horizontal and vertical dashed lines indicate +/- 2.5 standard deviations of
140 all sample medians (x-axis) and IQR's (y-axis). **B)** The sample-wise distributions of NPX values for the
141 Inflammation II panel. Boxplots of NPX values for each plasma sample along the x-axis and NPX values along
142 the y-axis. The center line represents the median. Plasma samples are colored by "QC_Warning" (Warning =
143 >0.3NPX from the median value of all samples on the plate). **C-D)** The first two principal components of 50
144 plasma samples and 359 proteins before and after batch correction with *Combat*.


145 **Elevated concentrations of plasma complement factors in *CRB1*-IRD patients**

146 We then compared the plasma proteome of patients to controls using linear models that
147 include age and sex (likelihood ratio test). At a *false discovery rate* of 5% ($q < 0.05$), we
148 detected 10 proteins with significantly different abundance between patients and controls
149 (**Figure 2A** and **Supplementary Table 3**). Among these, elevated levels were observed for
150 Complement Factor I [CFI], Complement factor H [CFH], protein S [PROS1], Serpin family D
151 member 1 [SERPIND1], and A Disintegrin-like And Metalloproteinase with ThromboSpondin
152 type 1 [ADAMTS1] in patients compared to healthy controls (**Figure 2B**). We also detected
153 significantly decreased levels for serine protease 22 [PRSS22] and microfibrillar-associated
154 protein 4 [MFAP4] in *CRB1*-IRD patients.

155 The 62 proteins most associated with *CRB1*-IRD patients (nominal $P < 0.05$) showed overall
156 considerable positive correlation in expression levels, with close clustering of CFI, CFH, C3,
157 and SERPIND1 (**Figure 2C**). These 62 proteins were strongly enriched for pathways
158 involving platelet biology, the complement system and coagulation cascades (**Figure 2D** and
159 **Supplementary Table 4**). In detail, the most enriched pathway was the "Complement
160 cascade" (e.g., *Reactome* pathway R-HSA-166658, $P_{adj} = P = 3.03 \times 10^{-15}$, **Figure 2D**). In
161 total, 12/62 *CRB1*-IRD associated proteins were linked to this pathway including the
162 significantly elevated proteins CFH, CFI, and PROS1. In addition, PROS1 and SERPIND1
163 were also linked to coagulation pathways (i.e., "Formation of Fibrin Clot (Clotting Cascade)",

Complement factors in *CRB1*-IRDs

164 $P_{adj} = P = 4.69 \times 10^{-7}$). Another enriched pathway included the “Extracellular matrix
 165 organization” (R-HSA-1474244, $P_{adj} = P = 5.84 \times 10^{-3}$) based on the significantly altered
 166 plasma proteins ADAMTS1 and MFAP4 (**Supplementary Table 4**). Collectively, these
 167 results show that elevated levels of complement factors and inflammation-related proteins
 168 characterized the plasma proteome of patients with *CRB1*-IRDs.



169

170 **Figure 2. Plasma complement and coagulation proteins are associated with *CRB1*-IRDs.** **A)** Volcano plot
 171 showing the $-\text{Log}_{10}(P\text{-values})$ versus the $\text{Log}_2(\text{mean NPX difference between groups})$ in plasma protein
 172 concentrations. Red indicates proteins with a significant increase in protein concentration and blue indicates
 173 proteins with a significant decrease in protein concentration in patients compared to controls. The dotted line
 174 indicates $P < 0.05$. **B)** Scatter plots of the levels of Complement Factor I [CFI], A Disintegrin-like And
 175 Metalloproteinase with ThromboSpondin type 1 [ADAMTS1], protein S [PROS1], and Serpin family D member 1

Complement factors in *CRB1*-IRDs

176 [SERPIND1] in plasma of patients (orange) and controls (blue). The median and the interquartile range (IQR) of
177 the distribution of Normalized Protein eXpression (NPX) values for each plasma sample is shown. **C)** Correlation
178 plot of the 62 proteins most associated with *CRB1*-IRDs ($P < 0.05$ from differential expression analysis). Red
179 indicates a positive correlation, white indicates no correlation, and blue indicates a negative correlation between
180 plasma protein analytes. **D)** Dot plot showing the top 10 results from enrichment analysis using the plasma
181 proteins associated with *CRB1*-IRDs as shown in C.

182 **The *CFH* genotype is altered in Dutch *CRB1*-IRD patients**


183 On chromosome 1, the *CRB1* gene is located adjacent to the *CFH-CFHR* locus, which is
184 implicated in other retinal conditions by influencing plasma complement protein levels and
185 other proteins detected in our study. Therefore, we hypothesized that linkage between *CRB1*
186 and the *CFH-CFHR* locus could influence the plasma proteome of *CRB1*-IRD patients. To
187 investigate this, we genotyped the common intronic SNP rs7535263 (LD $r^2 = 1.0$ with AMD
188 risk variant rs1410996 in CEU population of the 1000 Genomes). The genotype of
189 rs7535263 was shown to have the strongest correlation with the gene expression levels of
190 complement factors H related 1 to 4 (CFHR1-4) in *The Genotype-Tissue Expression* (GTEx)
191 project and is associated with multiple retinal diseases (e.g., AMD, multifocal choroiditis, and
192 serious chorioretinopathy) as well as with other immune mediators on our array, such as
193 CFP.³³⁻⁴⁰

194 The LD signatures of rs7535263 (r^2 and D' with linked SNPs) and genetic recombination
195 rates support that *CRB1* variants and *CFH-CFHR* variants may reside in the same haplotype
196 block (**Figure 3A and 3B**). As expected, the allele frequency of rs7535263 of Dutch controls
197 (A allele of rs7535263 = 0.34) was similar to that of the comparable North-European
198 populations of the 1000 genomes (0.36 in GBR [British in England and Scotland]
199 population). In contrast, the A allele of *CFH*-rs7535263 was significantly higher in frequency
200 in patients compared to controls (A allele of rs7535263, odds ratio (OR) [95%CI = 2.85
201 [1.35-6.02], $P = 6.19 \times 10^{-3}$) (**Figure 3C and 3D**). The most common *CRB1* variant in our
202 cohort was the homozygous p.(Met1041Thr) missense variants (*CRB1* c.3122T>C;

Complement factors in *CRB1*-IRDs

203 p.(Met1041Thr) found in 11/30 patients (37% of patients) which has been previously linked
204 to a large consanguineous pedigree originating from a genetically isolated population in the
205 Netherlands (**Figure 3E and 3F**). While this variant is rare in the general European
206 population (allele frequency = 0.00001 for rs62635656 in gnomAD database), the variant is
207 found relatively more common (>1%) in this specific geographical Dutch area
208 (**Supplementary Table 1**).⁴¹ We suspected that this deviation in allele frequency may
209 therefore be the result of biological relatedness among cases (i.e., founder effect). All
210 patients in our cohort homozygous for p.(Met1041Thr) were also homozygous for the A
211 allele of rs7535263, which results in an excess of homozygotes for the A allele of the *CFH*
212 variant rs7535263 and provides circumstantial evidence that biological relatedness between
213 cases may likely influence our analysis of plasma complement factors. In a validation cohort
214 of 123 *CRB1*-IRD cases from multiple countries and 1292 Dutch control participants the A
215 allele of rs7535263 was not significantly more frequent in patients compared to controls (A
216 allele of rs7535263, odds ratio (OR) [95%CI = 1.24 [0.95-1.61], $P = 0.12$). However, as in the
217 first cohort, a skewed allele frequency was observed for rs7535263 for the most common
218 *CRB1* variant p.(Cys948Tyr), also a common *CRB1* variant in previous reports,⁴² which
219 suggests linkage between specific variants of *CRB1* and *CFH*. Data from large population
220 databases such as the UK Biobank (UKB) may allow more accurate LD calculation between
221 missense variants in *CRB1* and rs7535263 in the *CFH* gene. To this end, we used phased
222 whole-genome sequencing data from the UK Biobank from ~150,000 individuals and
223 calculated LD for *CRB1* missense variants. Two *CRB1* missense variants commonly found
224 in *CRB1*-IRD cases with UKB allele frequencies that allow meaningful LD calculations (allele
225 frequency > 0.0001) display strong LD with rs7535263 in *CFH*,⁴³ the p.(Cys948Tyr) variant is
226 in LD with the G allele of rs7535263 ($D'=0.97$, UKB) and the p.(Arg764Cys) T allele is in full
227 LD ($D' = 1.0$ in UKB) with the A allele of rs7535263. Collectively these results confirm our
228 initial observation that patients with *CRB1* missense variants may co-inherit functional
229 variants in the adjacent *CFH* locus, which should be considered in quantitative analysis of
230 plasma complement factors in *CRB1*-IRD patients.

Complement factors in *CRB1*-IRDs



231


232 **Figure 3. Skewed allelic distribution for a common *CFH* variant in patients with *CRB1*-IRDs. A-B)** Linkage
 233 disequilibrium (r^2 metric left, and D' metric right) for rs7535263 in CEU superpopulation of the 1000 Genomes
 234 Project. Genes in the *complement factor H* (*CFH*) extended locus and *CRB1* are highlighted. **C)** Allele frequency
 235 distribution for rs7535263 in cohort 1 in cases and controls. **D)** The odds ratio, 95% confidence interval and P -
 236 value from Fischer's exact test for the A allele of rs7535263 in case-control analysis of cohort 1. **E)** The
 237 frequency of each *CRB1* pathogenic variant in cohort 1. **F)** Heatmap of the frequency of patients with rs7535263
 238 genotype and *CRB1* Met1041Thr variant dosage in cohort 1.

239 ***CRB1*-IRD patients show elevated plasma CFHR2 after adjusting for *CFH* genotype**

240 We investigated the effect of rs7535263 on the plasma concentrations of immune mediators
241 in healthy controls. In line with previous studies, the genotype of rs7535263 explained a
242 significant proportion of the plasma levels of several proteins encoded by genes in the
243 extended *CFH-CFHR* locus, including Complement factor H related protein 2 (CFHR2) ($R^2 =$
244 0.36), and CFHR4 ($R^2 = 0.24$), but not CFH ($R^2 = 0.003$) (**Supplementary Table 5 with R^2**
245 **values**), indicating that the genotype of this SNP may interfere with our analysis of some
246 proteins in *CRB1* patients. We therefore repeated our proteomic analysis for cohort 1 while
247 correcting for the genotype of rs7535263 (along with sex and age). This analysis revealed
248 that the association with the 10 significantly altered plasma proteins ($q < 0.05$) in our initial
249 group comparison were not significantly influenced by the genotype, such as CFI ($q_{rs7535263} =$
250 0.003), and CFH ($q_{rs7535263} = 0.06$) (**Figure 4A and 4B, Supplementary Table 3**) and all 10
251 remained within an FDR of 7% ($q < 0.07$). However, adjusting for rs7535263 revealed
252 additional proteins associated with *CRB1*-IRDs, most likely by improving statistical power by
253 reducing residual variance. Among these plasma proteins was CFHR2 ($q_{rs7535263} = 0.04$),
254 further supporting dysregulation of complement pathways in *CRB1*-IRDs (**Figure 4A and**
255 **4B**). Correcting for rs7535263 also revealed significant association ($q_{rs7535263} < 0.05$) with the
256 DNA binding protein ZBP1, and RNA helicase DDX39A, which was previously also
257 associated with the genotype of rs7535263 in multifocal choroiditis patients.³⁸

258 The identified complement factors CFI, CFH, and CFHR2 all target C3,^{44,45} an important
259 downstream effector of the complement system which was also increased in *CRB1*-IRD
260 patients, albeit at nominal significance ($q = 0.064$) (**Figure 4D**). Based on the profile of
261 complement factors in our array ($n = 18$), we performed a correlation analysis to identify the
262 factors associated with plasma C3 levels in our cohort. This analysis revealed that CFH and
263 CFI, but not CFHR2, strongly correlated with the levels of plasma C3 (**Figure 4C and 4D**).

Complement factors in *CRB1*-IRDs



264

265 **Figure 4. Elevated CFI and CFH levels correlate with plasma C3 in *CRB1*-IRDs.** **A)** Results from differential
 266 expression analysis before (x-axis) and after (y-axis) corrected for the genotype of rs7535263. The $-\log_{10}(P$
 267 value) for each protein analyte is shown. Red indicates proteins that became statistically significantly different
 268 between cases and controls after adjusting for the genotype of rs7535263 and the color black indicates the 10
 269 significant plasma proteins ($q < 0.05$) in our initial group comparison. Purple highlights plasma proteins involved in
 270 complement pathways. The dotted line indicates $P < 0.05$. **B)** Boxplots showing the levels for complement factor H
 271 [CFH] and complement factor H related 2 [CFHR2] in cases and controls in bulk and stratified by the genotype of
 272 *CFH* variant rs7535263. **C)** Correlation plot of the 18 proteins involved in complement pathways. Red indicates a
 273 positive correlation, white indicates no correlation, and blue indicates a negative correlation between plasma
 274 protein analytes. **D)** Boxplot and correlation plots of the levels of Complement Factor I [CFI], CFH, CFHR2, and
 275 complement component 3 [C3] in plasma in patients (orange) and controls (blue).

276 Discussion

277 In this study, we examined the plasma proteome of patients with *CRB1*-IRDs, whose levels
 278 of inflammation-related proteins and complement factors were notably elevated compared to
 279 healthy controls. A remarkable observation was the detection of elevated CFH and CFHR2

Complement factors in *CRB1*-IRDs

280 proteins in *CRB1*-IRDs because elevated plasma levels of CFHR2 have been linked with
281 other eye conditions, including AMD and multifocal choroiditis patients.^{12,33,34,38,46} CFH/CFHR
282 proteins are all involved in the regulation of the complement component C3,^{45,47} which was
283 supported by our observation of strong correlation between CFI and CFH with C3 in plasma.
284 Our results are also in line with animal models of IRDs (rd10 mice), which show an increase
285 in C3 protein levels and C3 activation, as well as an increase of mRNA of *cfh*, and *cfi* in the
286 retina.⁴⁸ While C3 is important for complement activation and can cause microglial activation
287 and photoreceptor cell injury,⁴⁹ it has also been shown to mediate retina-protective signaling
288 in other murine models of retinal degeneration but will require human trials with (intravitreal)
289 anti-C3 therapy to elucidate its potential as a therapeutic target for *CRB1*-IRDs.^{48,50,51}
290 Regardless, the increased levels of complement factors and inflammation-related proteins
291 that we found in patients support immune-mediated pathways involved in *CRB1*-IRDs.

292 Among the plasma proteins that were decreased in plasma of *CRB1*-IRD patients was the
293 extracellular protein MFAP4 that is ubiquitously expressed and plays a role in intracellular
294 interactions and cell adhesion. Macrophages drive local immune responses in retinal
295 degeneration^{52,53} and MFAP4 loss affects macrophage differentiation in animal models.⁵⁴
296 The elevated plasma levels of ADAMTS1 detected in *CRB1*-IRD patients may be related to
297 angiogenic responses, due to the vascular impairment secondary to degenerative changes
298 in the retina.⁵⁵⁻⁵⁸ The ADAMTS1 enzyme is an angiogenic matrix-modifying enzyme that is
299 upregulated by pro-inflammatory conditions in the retinal pigment epithelium (RPE).⁵⁹ We
300 also detected elevated levels of PROS1, a protein involved in the homeostasis of RPE.
301 Whole-exome sequencing has previously identified homozygous pathogenic variants in the
302 *PROS1* gene as causing retinal dystrophy in two unrelated families,⁶⁰ potentially disrupting
303 the vitamin K-dependent activities of PROS1, leading to RPE degradation. Further
304 investigation is needed to determine whether the elevated levels of PROS1 are caused by
305 retinal damage or by other biological events involving PROS1.

Complement factors in *CRB1*-IRDs

306 While the plasma proteome may reflect inflammation at the retinal level, it may also be
307 influenced by functional variants in complement factor coding genes. The *CRB1* gene is
308 located on chromosome 1 immediately downstream of the *CFH* locus. SNPs in the *CFH*
309 locus have been associated with several retinal conditions in which *CFH/CFHR* proteins
310 were also altered, including AMD, central serous chorioretinopathy, and multifocal
311 choroiditis,^{33–39} indicating that this locus could be an important disease-modifying locus for
312 eye conditions.

313 Using TaqMan® SNP genotyping technology, we found evidence for skewed distribution of
314 functional variants in the *CFH* gene which may predispose to altered complement factor
315 levels in *CRB1*-IRDs or obscure relevant disease associations with plasma proteins, as
316 demonstrated by our work. The significant skewing of the common *CFH* variants across
317 *CRB1* pathogenic variants in our Dutch cohort is likely the result of frequent consanguineous
318 marriages in geographically more isolated populations, such as the strict geographical
319 location of the p.(Met1041Thr) in the Netherlands and predisposes to homozygosity of
320 harmful recessive alleles. Genotype frequencies, Hardy-Weinberg equilibrium assumptions,
321 and allele frequencies can be affected by relatedness and our study demonstrates that
322 addressing relatedness is crucial to ensure the accuracy of genotype-disease relationships
323 and assessment of quantification of the complement factors in *CRB1*-IRDs and other family-
324 based monogenic conditions. We believe this genetic “confounding” of common variants is
325 currently strongly underappreciated in molecular profiling studies of *CRB1*-IRDs.

326 While we show that in a second global cohort there is no association with the *CFH/CFHR*
327 locus in *CRB1* cases in general, data from the well-powered UK Biobank demonstrated
328 linkage between variants in *CFH* and *CRB1*. Several key missense variants (e.g.,
329 p.(Cys948Tyr)) are nearly exclusively inherited with one of the two alleles of rs7535263,
330 which tag functionally distinct *CFH/CFHR* haplotypes and predispose to altered composition
331 of plasma complement factors.^{11,12} This linkage is expected from their proximity on the
332 genome and LD signatures in the general population and has important implications for

Complement factors in *CRB1*-IRDs

333 future research and treatment modalities: 1) Our study demonstrates that complement factor
334 components are involved in *CRB1*-IRDs, but that relative biological relatedness (i.e., founder
335 effects) between individuals or linkage with functional variants in the *CFH* locus should be
336 considered in follow-up studies of complement dysregulation in human studies of *CRB1*-
337 IRDs. 2) While we demonstrate that correcting for the genotype of rs7535263 revealed an
338 otherwise obscured increase in CFHR2 levels in patients, it is not unlikely that additional
339 CFH(R) gene variants that genetically predispose to altered complement factor levels
340 contribute to the pathophysiology of *CRB1*-IRDs. The limited sample size of our study and
341 the lack of probing for other CFH-related factors encoded by genes upstream of the *CRB1*
342 locus (e.g., CFHR1 and CFHR3 levels correlate with genotype of rs7535263 according to
343 *gtexportal*) may have resulted in an underestimation of the differences in the levels of
344 complement factors in *CRB1*-IRD patients compared to controls. 3) Many more common
345 variants in immune genes are likely involved in disease-modifying pathways that may
346 influence the severity and disease course of *CRB1*-IRDs. The use of genome-wide
347 association studies using well defined clinical endpoints, preferably based on
348 microperimetry,⁶¹ may aid in the discovery of these common variants and could improve
349 genotype-phenotype correlations to better predict disease course, and perhaps lead to
350 therapeutic modalities that can alter the disease course. The latter may be also of interest for
351 emerging *CRB1* gene-augmentation therapy or mutational correction by allelic substitution
352 via CRISPR/Cas9-mediated homology-directed repair or base editing,^{62,63} because these
353 therapeutic approaches are accompanied by immune activation when administered
354 intravitreally or subretinally.⁶⁴ It would be important to determine to what extent the
355 inflammatory markers identified in this study may help understand the side effects of gene
356 therapy, such as increased chorioretinal atrophy that has recently been described after gene
357 therapy using *voretigene neparvovec* for *RPE65*-associated retinal dystrophies.^{65,66} A major
358 source of plasma complement components is the liver, but complement proteins are also
359 produced and expressed in the retina, as well as by immune cells and various tissues.
360 Complement activation may occur in the retina due to loss of tissue integrity caused by

Complement factors in *CRB1*-IRDs

361 *CRB1* dysfunction, and modulating the complement system without addressing this primary
362 cause may not have a clinically significant impact on the progression of the disease.
363 Regardless, a complement-targeted therapy may be useful as a combination therapy to
364 minimize adverse reactions from *CRB1* gene correcting strategies in retinal degeneration,
365 and potentially even in other gene therapy strategies for IRDs. In future studies, it might be
366 informative to determine the immune profile of patients prior to commencing gene therapy
367 interventions, to determine to what extent complement activation and plasma concentrations
368 influence outcome in patients.

369 In conclusion, our results implicate the involvement of the complement cascade in *CRB1*-
370 IRDs. For future research, gene association studies of all SNPs in the genome with a
371 categorization of patients based on disease severity may provide more insight into the
372 pathophysiology of *CRB1*-IRDs, and IRDs in general.

373 **Acknowledgements**

374 Dr. N.H. ten Dam-van Loon, Dr. J. Ossewaarde-van Norel, and Dr. V. Koopman-Kalinina
375 Ayuso for their assistance performing slit lamp examination and assessment of vitreous cells
376 and vitreous haze on all included patients.

377 **References**

- 378 1. Bujakowska K, Audo I, Mohand-Säid S, et al. *CRB1* mutations in inherited retinal
379 dystrophies. *Hum Mutat* 2012;33:306. Available at: [/pmc/articles/PMC3293109/](https://pubmed.ncbi.nlm.nih.gov/11389483/) [Accessed
380 August 7, 2022].
- 381 2. Den Hollander AI, Heckenlively JR, van den Born LI, et al. Leber congenital amaurosis
382 and retinitis pigmentosa with Coats-like exudative vasculopathy are associated with
383 mutations in the crumbs homologue 1 (*CRB1*) gene. *Am J Hum Genet* 2001;69:198–203.
384 Available at: <https://pubmed.ncbi.nlm.nih.gov/11389483/> [Accessed September 6, 2023].
- 385 3. Den Hollander AI, Davis J, Van Der Velde-Visser SD, et al. *CRB1* mutation spectrum in
386 inherited retinal dystrophies. *Hum Mutat* 2004;24:355–369. Available at:
387 <https://pubmed.ncbi.nlm.nih.gov/15459956/> [Accessed September 6, 2023].
- 388 4. Talib M, Van Cauwenbergh C, De Zaeytijd J, et al. *CRB1*-associated retinal dystrophies in
389 a Belgian cohort: genetic characteristics and long-term clinical follow-up. *British Journal of*
390 *Ophthalmology* 2022;106:696–704. Available at: [https://bjo-bmj-](https://bjo-bmj-com.proxy.library.uu.nl/content/106/5/696)
391 [com.proxy.library.uu.nl/content/106/5/696](https://bjo-bmj-com.proxy.library.uu.nl/content/106/5/696) [Accessed October 3, 2023].
- 392 5. Hettinga YM, van Genderen MM, Wieringa W, et al. Retinal Dystrophy in 6 Young Patients
393 Who Presented with Intermediate Uveitis. *Ophthalmology* 2016;123:2043–2046. Available
394 at: <https://pubmed.ncbi.nlm.nih.gov/27157150/> [Accessed February 21, 2023].
- 395 6. Verhagen F, Kuiper J, Nierkens S, et al. Systemic inflammatory immune signatures in a
396 patient with *CRB1* linked retinal dystrophy. *Expert Rev Clin Immunol* 2016;12:1359–1362.
397 Available at: <https://pubmed.ncbi.nlm.nih.gov/27690673/> [Accessed February 21, 2023].
- 398 7. Watson CM, El-Asrag M, Parry DA, et al. Mutation screening of retinal dystrophy patients
399 by targeted capture from tagged pooled DNAs and next generation sequencing. *PLoS One*
400 2014;9. Available at: <https://pubmed.ncbi.nlm.nih.gov/25133751/> [Accessed August 8, 2022].
- 401 8. De Castro-Miró M, Pomares E, Lorés-Motta L, et al. Combined genetic and high-
402 throughput strategies for molecular diagnosis of inherited retinal dystrophies. *PLoS One*
403 2014;9. Available at: <https://pubmed.ncbi.nlm.nih.gov/24516651/> [Accessed August 8, 2022].
- 404 9. Alves CH, Wijnholds J. Microglial Cell Dysfunction in *CRB1*-Associated Retinopathies.
405 *Adv Exp Med Biol* 2019;1185:159–163. Available at: [https://link-springer-](https://link-springer-com.proxy.library.uu.nl/chapter/10.1007/978-3-030-27378-1_26)
406 [com.proxy.library.uu.nl/chapter/10.1007/978-3-030-27378-1_26](https://link-springer-com.proxy.library.uu.nl/chapter/10.1007/978-3-030-27378-1_26) [Accessed August 8, 2022].
- 407 10. Moekotte L, Kuiper JJW, Hiddingh S, et al. *CRB1*-Associated Retinal Dystrophy Patients
408 Have Expanded Lewis Glycoantigen-Positive T Cells. *Invest Ophthalmol Vis Sci* 2023;64:6.
409 Available at: <https://pubmed.ncbi.nlm.nih.gov/37792335/> [Accessed October 10, 2023].
- 410 11. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome.
411 *Nature* 2018;558:73–79. Available at: <https://pubmed.ncbi.nlm.nih.gov/29875488/> [Accessed
412 September 7, 2023].
- 413 12. Emilsson V, Gudmundsson EF, Jonmundsson T, et al. A proteogenomic signature of
414 age-related macular degeneration in blood. *Nat Commun* 2022;13. Available at:
415 <https://pubmed.ncbi.nlm.nih.gov/35697682/> [Accessed September 7, 2023].
- 416 13. Lynch AM, Wagner BD, Mandava N, et al. The Relationship of Novel Plasma Proteins in
417 the Early Neonatal Period With Retinopathy of Prematurity. *Invest Ophthalmol Vis Sci*
418 2016;57:5076–5082. Available at: <https://pubmed.ncbi.nlm.nih.gov/27679852/> [Accessed
419 September 7, 2023].
- 420 14. Kuiper JJW, Verhagen FH, Hiddingh S, et al. A Network of Serum Proteins Predict the
421 Need for Systemic Immunomodulatory Therapy at Diagnosis in Noninfectious Uveitis.
422 *Ophthalmology science* 2022;2. Available at: <https://pubmed.ncbi.nlm.nih.gov/36245752/>
423 [Accessed September 7, 2023].

Complement factors in *CRB1*-IRDs

- 424 15. Achten R, van Luijk C, Thijs J, et al. Non-Infectious Uveitis Secondary to Dupilumab
425 Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile. *Ocul*
426 *Immunol Inflamm* 2023. Available at: <https://pubmed.ncbi.nlm.nih.gov/36854134/> [Accessed
427 September 7, 2023].
- 428 16. Wennink RAW, Ayuso VK, Tao W, et al. A Blood Protein Signature Stratifies Clinical
429 Response to csDMARD Therapy in Pediatric Uveitis. *Transl Vis Sci Technol* 2022;11.
430 Available at: <https://pubmed.ncbi.nlm.nih.gov/35103800/> [Accessed September 7, 2023].
- 431 17. Wierenga APA, Cao J, Mouthaan H, et al. Aqueous Humor Biomarkers Identify Three
432 Prognostic Groups in Uveal Melanoma. *Invest Ophthalmol Vis Sci* 2019;60:4740–4747.
433 Available at: <https://pubmed.ncbi.nlm.nih.gov/31731294/> [Accessed September 7, 2023].
- 434 18. Haq Z, Yang D, Psaras C, Stewart JM. Sex-Based Analysis of Potential Inflammation-
435 Related Protein Biomarkers in the Aqueous Humor of Patients With Diabetes Mellitus. *Transl*
436 *Vis Sci Technol* 2021;10:1–8. Available at: <https://pubmed.ncbi.nlm.nih.gov/34003946/>
437 [Accessed September 7, 2023].
- 438 19. Machiela MJ, Chanock SJ. LDassoc: an online tool for interactively exploring genome-
439 wide association study results and prioritizing variants for functional investigation.
440 *Bioinformatics* 2018;34:887–889. Available at: <https://pubmed.ncbi.nlm.nih.gov/28968746/>
441 [Accessed September 7, 2023].
- 442 20. Anon. Index of /vol1/ftp/technical/working/20130507_omni_recombination_rates.
443 Available at:
444 https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination
445 [_rates/](https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination) [Accessed October 10, 2023].
- 446 21. Chang CC, Chow CC, Tellier LCAM, et al. Second-generation PLINK: rising to the
447 challenge of larger and richer datasets. *Gigascience* 2015;4. Available at:
448 <https://pubmed.ncbi.nlm.nih.gov/25722852/> [Accessed October 4, 2023].
- 449 22. Hofmeister RJ, Ribeiro DM, Rubinacci S, Delaneau O. Accurate rare variant phasing of
450 whole-genome and whole-exome sequencing data in the UK Biobank. *Nat Genet*
451 2023;55:1243–1249. Available at: <https://pubmed.ncbi.nlm.nih.gov/37386248/> [Accessed
452 October 10, 2023].
- 453 23. Yeung MW, Wang S, Van De Vegte YJ, et al. Twenty-Five Novel Loci for Carotid Intima-
454 Media Thickness: A Genome-Wide Association Study in >450,000 Individuals and Meta-
455 Analysis of >1000,000 Individuals. *Arterioscler Thromb Vasc Biol* 2022;42:484–501.
456 Available at: [https://www-ahajournals-](https://www-ahajournals-org.proxy.library.uu.nl/doi/abs/10.1161/ATVBAHA.121.317007)
457 [org.proxy.library.uu.nl/doi/abs/10.1161/ATVBAHA.121.317007](https://www-ahajournals-org.proxy.library.uu.nl/doi/abs/10.1161/ATVBAHA.121.317007) [Accessed October 10, 2023].
- 458 24. van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant
459 association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic
460 architectures and neuron-specific biology. *Nat Genet* 2021;53:1636–1648. Available at:
461 <https://pubmed.ncbi.nlm.nih.gov/34873335/> [Accessed November 2, 2023].
- 462 25. Panneman DM, Hitti-Malin RJ, Holtes LK, et al. Cost-effective sequence analysis of 113
463 genes in 1,192 probands with retinitis pigmentosa and Leber congenital amaurosis. *Front*
464 *Cell Dev Biol* 2023;11. Available at: <https://pubmed.ncbi.nlm.nih.gov/36819107/> [Accessed
465 September 26, 2023].
- 466 26. Anon. Olink Data normalization and standardization.
- 467 27. Anon. Facilitate Analysis of Proteomic Data from Olink [R package OlinkAnalyze version
468 3.5.1]. 2023. Available at: <https://CRAN.R-project.org/package=OlinkAnalyze> [Accessed
469 October 11, 2023].
- 470 28. Storey J, Bass A, Dabney A, Robinson D. qvalue: Q-value estimation for false discovery
471 rate control. 2023.

Complement factors in *CRB1*-IRDs

- 472 29. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting
473 omics data. *Innovation (Cambridge (Mass))* 2021;2. Available at:
474 <https://pubmed.ncbi.nlm.nih.gov/34557778/> [Accessed April 4, 2023].
- 475 30. Anon. Chapter 15 Visualization of functional enrichment result | Biomedical Knowledge
476 Mining using GOSemSim and clusterProfiler. Available at: [https://yulab-smu.top/biomedical-
477 knowledge-mining-book/enrichplot.html](https://yulab-smu.top/biomedical-
477 knowledge-mining-book/enrichplot.html) [Accessed April 4, 2023].
- 478 31. Wei T, Simko V. R package “corrplot”: Visualization of a Correlation Matrix. 2021.
- 479 32. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2016.
- 480 33. Cipriani V, Lorés-Motta L, He F, et al. Increased circulating levels of Factor H-Related
481 Protein 4 are strongly associated with age-related macular degeneration. *Nat Commun*
482 2020;11. Available at: <https://pubmed.ncbi.nlm.nih.gov/32034129/> [Accessed September 7,
483 2023].
- 484 34. Lorés-Motta L, van Beek AE, Willems E, et al. Common haplotypes at the CFH locus and
485 low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations
486 and age-related macular degeneration. *Am J Hum Genet* 2021;108:1367–1384. Available at:
487 <https://pubmed.ncbi.nlm.nih.gov/34260947/> [Accessed September 7, 2023].
- 488 35. den Hollander AI, Mullins RF, Orozco LD, et al. Systems genomics in age-related
489 macular degeneration. *Exp Eye Res* 2022;225. Available at:
490 <https://pubmed.ncbi.nlm.nih.gov/36108770/> [Accessed September 7, 2023].
- 491 36. Kaye R, Chandra S, Sheth J, et al. Central serous chorioretinopathy: An update on risk
492 factors, pathophysiology and imaging modalities. *Prog Retin Eye Res* 2020;79. Available at:
493 <https://pubmed.ncbi.nlm.nih.gov/32407978/> [Accessed September 7, 2023].
- 494 37. Schellevis RL, Van Dijk EHC, Breukink MB, et al. Role of the Complement System in
495 Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study. *JAMA*
496 *Ophthalmol* 2018;136:1128–1136. Available at: <https://pubmed.ncbi.nlm.nih.gov/30073298/>
497 [Accessed September 7, 2023].
- 498 38. de Groot EL, Ossewaarde-van Norel J, de Boer JH, et al. Association of Risk Variants in
499 the CFH Gene With Elevated Levels of Coagulation and Complement Factors in Idiopathic
500 Multifocal Choroiditis. *JAMA Ophthalmol* 2023;141. Available at:
501 <https://pubmed.ncbi.nlm.nih.gov/37410486/> [Accessed September 7, 2023].
- 502 39. Ferrara DC, Merriam JE, Freund KB, et al. Analysis of major alleles associated with age-
503 related macular degeneration in patients with multifocal choroiditis: strong association with
504 complement factor H. *Arch Ophthalmol* 2008;126:1562–1566. Available at:
505 <https://pubmed.ncbi.nlm.nih.gov/19001225/> [Accessed September 7, 2023].
- 506 40. Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma
507 proteome with genetics and disease. *Nat Genet* 2021;53:1712–1721. Available at:
508 <https://pubmed.ncbi.nlm.nih.gov/34857953/> [Accessed September 7, 2023].
- 509 41. Den Hollander AI, Ten Brink JB, De Kok YJM, et al. Mutations in a human homologue of
510 *Drosophila crumbs* cause retinitis pigmentosa (RP12). *Nat Genet* 1999;23:217–221.
511 Available at: <https://pubmed.ncbi.nlm.nih.gov/10508521/> [Accessed September 7, 2023].
- 512 42. Kousal B, Dudakova L, Gailylova R, et al. Phenotypic features of *CRB1*-associated early-
513 onset severe retinal dystrophy and the different molecular approaches to identifying the
514 disease-causing variants. *Graefes Arch Clin Exp Ophthalmol* 2016;254:1833–1839.
515 Available at: <https://pubmed.ncbi.nlm.nih.gov/27113771/> [Accessed September 7, 2023].
- 516 43. Lopes da Costa B, Kolesnikova M, Levi SR, et al. Clinical and Therapeutic Evaluation of
517 the Ten Most Prevalent *CRB1* Mutations. *Biomedicines* 2023;11. Available at:
518 <https://pubmed.ncbi.nlm.nih.gov/36830922/> [Accessed October 4, 2023].



Complement factors in *CRB1*-IRDs

- 519 44. Whaley K, Ruddy S. Modulation of C3b hemolytic activity by a plasma protein distinct
520 from C3b inactivator. *Science* 1976;193:1011–1013. Available at:
521 <https://pubmed.ncbi.nlm.nih.gov/948757/> [Accessed September 7, 2023].
- 522 45. Eberhardt HU, Buhlmann D, Hortschansky P, et al. Human factor H-related protein 2
523 (CFHR2) regulates complement activation. *PLoS One* 2013;8. Available at:
524 <https://pubmed.ncbi.nlm.nih.gov/24260121/> [Accessed September 7, 2023].
- 525 46. Cipriani V, Tierney A, Griffiths JR, et al. Beyond factor H: The impact of genetic-risk
526 variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-
527 related protein concentrations. *Am J Hum Genet* 2021;108:1385–1400. Available at:
528 <https://pubmed.ncbi.nlm.nih.gov/34260948/> [Accessed September 7, 2023].
- 529 47. Cserhalmi M, Papp A, Brandus B, et al. Regulation of regulators: Role of the
530 complement factor H-related proteins. *Semin Immunol* 2019;45. Available at:
531 <https://pubmed.ncbi.nlm.nih.gov/31757608/> [Accessed September 7, 2023].
- 532 48. Silverman SM, Ma W, Wang X, et al. C3- and CR3-dependent microglial clearance
533 protects photoreceptors in retinitis pigmentosa. *J Exp Med* 2019;216:1925–1943.
- 534 49. Wang S, Du L, Yuan S, Peng GH. Complement C3a receptor inactivation attenuates
535 retinal degeneration induced by oxidative damage. *Front Neurosci* 2022;16. Available at:
536 <https://pubmed.ncbi.nlm.nih.gov/36110094/> [Accessed September 7, 2023].
- 537 50. Hoh Kam J, Lenassi E, Malik TH, et al. Complement component C3 plays a critical role
538 in protecting the aging retina in a murine model of age-related macular degeneration. *Am J*
539 *Pathol* 2013;183:480–492. Available at: <https://pubmed.ncbi.nlm.nih.gov/23747511/>
540 [Accessed September 7, 2023].
- 541 51. Wykoff CC, Hershberger V, Eichenbaum D, et al. Inhibition of Complement Factor 3 in
542 Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. *Am J*
543 *Ophthalmol* 2022;235:131–142. Available at: <https://pubmed.ncbi.nlm.nih.gov/34509438/>
544 [Accessed September 7, 2023].
- 545 52. Yu C, Roubeyx C, Sennlaub F, Saban DR. Microglia versus Monocytes: Distinct Roles in
546 Degenerative Diseases of the Retina. *Trends Neurosci* 2020;43:433–449. Available at:
547 <https://pubmed.ncbi.nlm.nih.gov/32459994/> [Accessed September 7, 2023].
- 548 53. Guo M, Schwartz TD, Dunaief JL, Cui QN. Myeloid cells in retinal and brain
549 degeneration. *FEBS J* 2022;289:2337–2361. Available at:
550 <https://pubmed.ncbi.nlm.nih.gov/34478598/> [Accessed September 7, 2023].
- 551 54. Ong SLM, de Vos IJHM, Meroshini M, et al. Microfibril-associated glycoprotein 4 (Mfap4)
552 regulates haematopoiesis in zebrafish. *Sci Rep* 2020;10. Available at:
553 <https://pubmed.ncbi.nlm.nih.gov/32678226/> [Accessed September 7, 2023].
- 554 55. Rajabian F, Arrigo A, Bianco L, et al. Optical Coherence Tomography Angiography in
555 *CRB1*-Associated Retinal Dystrophies. *J Clin Med* 2023;12. Available at:
556 <https://pubmed.ncbi.nlm.nih.gov/36769743/> [Accessed September 7, 2023].
- 557 56. Murro V, Mucciolo DP, Sodi A, et al. Retinal capillaritis in a *CRB1*-associated retinal
558 dystrophy. *Ophthalmic Genet* 2017;38:555–558. Available at:
559 <https://doi.org/10.1080/13816810.2017.1281966>.
- 560 57. Alonso F, Dong Y, Li L, et al. Fibrillin-1 regulates endothelial sprouting during
561 angiogenesis. *Proc Natl Acad Sci U S A* 2023;120. Available at:
562 <https://pubmed.ncbi.nlm.nih.gov/37252964/> [Accessed September 7, 2023].
- 563 58. Talib M, van Schooneveld MJ, van Genderen MM, et al. Genotypic and Phenotypic
564 Characteristics of *CRB1*-Associated Retinal Dystrophies: A Long-Term Follow-up Study.
565 *Ophthalmology* 2017;124:884–895. Available at: <https://pubmed.ncbi.nlm.nih.gov/28341475/>
566 [Accessed February 21, 2023].


Complement factors in *CRB1*-IRDs

- 567 59. Bevitt DJ, Mohamed J, Catterall JB, et al. Expression of ADAMTS metalloproteinases in
568 the retinal pigment epithelium derived cell line ARPE-19: Transcriptional regulation by TNF α .
569 *Biochimica et Biophysica Acta - Gene Structure and Expression* 2003;1626:83–91. Available
570 at: <https://pubmed.ncbi.nlm.nih.gov/12697333/> [Accessed September 7, 2023].
- 571 60. Bushehri A, Zare-Abdollahi D, Alavi A, et al. Identification of PROS1 as a Novel
572 Candidate Gene for Juvenile Retinitis Pigmentosa. *Int J Mol Cell Med* 2019;8:179–190.
573 Available at: <https://pubmed.ncbi.nlm.nih.gov/32489947/> [Accessed September 7, 2023].
- 574 61. Nguyen XTA, Talib M, van Schooneveld MJ, et al. *CRB1*-Associated Retinal
575 Dystrophies: A Prospective Natural History Study in Anticipation of Future Clinical Trials. *Am*
576 *J Ophthalmol* 2022;234:37–48. Available at: <https://pubmed.ncbi.nlm.nih.gov/34320374/>
577 [Accessed October 3, 2023].
- 578 62. Boon N, Lu X, Andriessen CA, et al. AAV-mediated gene augmentation therapy of *CRB1*
579 patient-derived retinal organoids restores the histological and transcriptional retinal
580 phenotype. *Stem Cell Reports* 2023;18:1123–1137. Available at:
581 <https://pubmed.ncbi.nlm.nih.gov/37084726/> [Accessed September 7, 2023].
- 582 63. da Costa BL, Li Y, Levi SR, et al. Generation of *CRB1* RP Patient-Derived iPSCs and a
583 CRISPR/Cas9-Mediated Homology-Directed Repair Strategy for the *CRB1* c.2480G>T
584 Mutation. *Adv Exp Med Biol* 2023;1415:571–576. Available at:
585 <https://pubmed.ncbi.nlm.nih.gov/37440088/> [Accessed September 7, 2023].
- 586 64. Nguyen X-T-A, Moekotte L, Plomp AS, et al. Retinitis Pigmentosa: Current Clinical
587 Management and Emerging Therapies. *Int J Mol Sci* 2023;24:7481. Available at:
588 <https://www.mdpi.com/1422-0067/24/8/7481> [Accessed April 19, 2023].
- 589 65. Gange WS, Sisk RA, Besirli CG, et al. Perifoveal Chorioretinal Atrophy after Subretinal
590 Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis. *Ophthalmol*
591 *Retina* 2022;6:58–64. Available at: <https://pubmed.ncbi.nlm.nih.gov/33838313/> [Accessed
592 September 7, 2023].
- 593 66. Reichel FF, Seitz I, Wozar F, et al. Development of retinal atrophy after subretinal gene
594 therapy with voretigene neparvovec. *Br J Ophthalmol* 2023;107. Available at:
595 <https://pubmed.ncbi.nlm.nih.gov/35609955/> [Accessed September 7, 2023].
596

Complement factors in *CRB1*-IRDs



C Before *ComBat* correction (n=50)



D After *ComBat* correction (n=50)

